1.Development and Validation of an Attitudinal-Profiling Tool for Patients With Asthma.
Aileen DAVID-WANG ; David PRICE ; Sang Heon CHO ; James Chung Man HO ; Chong Kin LIAM ; Glenn NEIRA ; Pei Li TEH
Allergy, Asthma & Immunology Research 2017;9(1):43-51
PURPOSE: To develop a profiling tool which accurately assigns a patient to the appropriate attitudinal cluster for the management of asthma. METHODS: Attitudinal data from an online survey of 2,467 patients with asthma from 8 Asian countries/region, aged 18-50 years, having had ≥2 prescriptions in the previous 2 years and access to social media was used in a discriminant function analysis to identify a minimal set of questions for the Profiling Tool. A split-sample procedure based on 100 sets of randomly selected estimation and validation sub-samples from the original sample was used to cross-validate the Tool and assess the robustness of its predictive accuracy. RESULTS: Our Profiling Tool contained 10 attitudinal questions for the patient and 1 GINA-based level of asthma control question for the physician. It achieved a predictive accuracy of 76.2%. The estimation and validation sub-sample accuracies of 76.7% and 75.3%, respectively, were consistent with the tool's predictive accuracy at 95% confidence level; and their 1.4 percentage-points difference set upper-bound estimate for the degree of over-fitting. CONCLUSIONS: The Profiling Tool is highly predictive (>75%) of the attitudinal clusters that best describe patients with asthma in the Asian population. By identifying the attitudinal profile of the patient, the physician can make the appropriate asthma management decisions in practice. The challenge is to integrate its use into the consultation workflow and apply to areas where Internet resources are not available or patients who are not comfortable with the use of such technology.
Asia
;
Asian Continental Ancestry Group
;
Asthma*
;
Discriminant Analysis
;
Disease Management
;
Humans
;
Internet
;
Prescriptions
;
Social Media
2.Association of metabolic syndrome with the severity of airflow obstruction in patients with chronic obstructive pulmonary disease.
Gherald Bermudez ; Gabriel Jasul Jr. ; Aileen David-Wang ; Cecilia Jimeno ; Jonray Magallanes ; Anna Angelica Macalalad-Josue
Journal of the ASEAN Federation of Endocrine Societies 2018;33(2):181-187
BACKGROUND. Metabolic Syndrome (MetS) is common in Chronic Obstructive Pulmonary Disease (COPD) patients but their association is still an unsettled issue. The aim of this study was to determine the association of MetS with the severity of airflow obstruction.
METHODOLOGY. This was a cross-sectional analytic study of 157 patients with COPD. They were classified using the Global Initiative for Chronic Obstructive Lung Diseases (GOLD). MetS was assessed using two well-recognized criteria. Demographics, clinical data, lifestyle-related characteristics, fasting blood sugar (FBS) and lipid profile were obtained. Multiple logistic regression was used to determine the association of MetS with the severity of airflow obstruction.
RESULTS. 40.13% and 17.20% of patients had MetS using the NCEP/ATP III-AHA/NHBLI and IDF criteria, respectively. MetS was not associated with severity of airflow obstruction. Of the MetS components, only elevated blood pressure (BP) was significantly associated with severity of airflow obstruction (GOLD II: OR=3.28, p<0.001; GOLD III: OR=4.04, p=0.2; GOLD IV: OR=6.21, p=0.04). Elevated FBS was also associated with GOLD IV (OR=16.09, p=0.02). Significant factors associated with MetS in COPD patients were body mass index, inhaled steroid, number of pack-years, and GOLD II.
CONCLUSION. MetS is not associated with severity of airflow obstruction. Only certain components of MetS showed significant associations such as elevated BP with GOLD II-IV and elevated FBS with GOLD IV.
Human ; Male ; Female ; Aged 80 And Over ; Aged (a Person 65 Through 79 Years Of Age) ; Middle Aged (a Person 45-64 Years Of Age)
3.Validation of Filipino version of a questionnaire on work- related asthma among healthcare workers of the Philippine General Hospital: A prospective cross-sectional study
Joel M. Santiaguel ; Mary Grace P. Quilloy-Arellano ; Adele H. Espaldon ; Maria Philina B. Pablo ; Aileen S. David-Wang ; Mithi Kalayaan S. Zamora
Philippine Journal of Internal Medicine 2023;61(3):149-163
Objective:
This study aims to validate a Filipino version of the questionnaire by Delclos et al on occupational risk factors and asthma among the health care workers of the Philippine General Hospital.
Methodology:
Forward and backward translation method for bilinguals was used in this study. The Filipino translation was administered to 110 health care workers selected by stratified random sampling. After 24 hours, the retranslated English version was given to the same respondents. Testing for internal consistency reliability was done by computing for Cronbach's alpha. Construct validity was subsequently determined using the Cramer's V Coefficient.
Results:
The Filipino questionnaire showed good internal consistency reliability, as shown by the overall Cronbach’s alpha of 0.9016, which is comparable to that of the original version by Delclos. Likewise, our Filipino questionnaire showed good construct validity, supported by the Cramer’s V coefficients ranging from 0.2204 (strong relationship) to 0.7843 (very strong relationship).
Conclusion
Overall, the Filipino version of the questionnaire for work-related asthma tested among the health care
workers of Philippine General Hospital showed good reliability and validity. This may now be used as screening tool for occupational asthma among health care workers who are at risk of developing the disease. In addition, this research tool may be utilized to establish the prevalence of occupational asthma in hospitals and later on, aid in the development of a better working environment for the whole health care team.
Health Personnel
;
Surveys and Questionnaires
4.The prevalence of CYP2D6 Gene Polymorphisms among Filipinos and their use as biomarkers for lung cancer risk
Eva Maria Cutiongco-de la Paz ; Corazon A. Ngelangel ; Aileen David-Wang ; Jose B. Nevado Jr. ; Catherine Lynn T. Silao ; Rosalyn Hernandez-Sebastian ; Richmond B. Ceniza ; Leander Linus Philip P. Simpao ; Lakan U. Beratio ; Eleanor A. Dominguez ; Albert B. Albay Jr ; Rey A. Desales ; Nelia Tan-Liu ; Sullian Sy-Naval ; Roberto M. Montevirgen ; Catalina de Siena Gonda-Dimayacyac ; Pedrito Y. Tagayuna ; Elizabeth A. Nuqui ; Arnold Joseph M. Fernandez ; Andrew D. Dimacali ; Maria Constancia Obrerro-Carrillo ; Virgilio P. Banez ; Oliver G. Florendo G. Florendo ; Ma. Cecilia M. Sison ; Francisco T. Roxas ; Alberto B. Roxas ; Orlino C. Bisquera Jr. ; Luminardo M. Ramos ; John A. Coloma ; Higinio T. Mappala ; Alex C. Tapia ; Emmanuel F. Montana Jr. ; Jonathan M. Asprer ; Reynaldo O. Joson ; Sergio P. Paguio ; Conrado C. Cajucom ; Richard C. Tia ; Tristan Chipongian ; Joselito F. David ; Florentino C. Doble ; Maria Noemi G. Pato ; Hans Francis D. Ferraris ; Benito B. Bionat Jr. ; Adonis A. Guancia ; Eriberto R. Layda ; Frances Maureen C. Rocamora ; Roemel Jeusep Bueno ; Carmencita D. Padilla
Acta Medica Philippina 2017;51(3):207-215
Objectives:
The highly polymorphic nature of the CYP2D6 gene and its central role in the metabolism of commonly used drugs make it an ideal candidate for pharmacogenetic screening. This study aims to determine the prevalence of CYP2D6 polymorphisms among Filipinos and their association to lung cancer.
Method:
Forty seven single nucleotide polymorphisms (SNPs) of the CYP2D6 gene were genotyped from DNA samples of 115 cases with lung cancer and age- and sex-matched 115 controls.
Results:
Results show that 18 out of 47 polymorphisms have significant genotypic variability (>1% for at least 2 genotypes). No variant is associated with lung cancer. However, rs1135840,
rs16947 and rs28360521, were found to be highly variable among Filipinos.
Conclusion
This study demonstrated that CYP2D6 polymorphisms are present among Filipinos, which, although not found to be associated with lung cancer, can be useful biomarkers for future pharmacogenetic studies. The SNP rs16947 is found to be associated with cancer and timolol-induced bradycardia; the SNP rs1135840, on the other hand, is only shown to be linked with cancer. The genetic variant rs28360521 is known to be associated with low-dose aspirin-induced lower gastrointestinal bleeding.
Pharmacogenetics
;
Cytochrome P-450 CYP2D6
;
Lung Neoplasms
;
Biomarkers
5.Genetic polymorphisms in NAT1, NAT2, GSTM1, GSTP1 and GSTT1 and susceptibility to colorectal cancer among Filipinos
Eva Maria C. Cutiongco-de la Paz ; Corazon A. Ngelangel ; Virgilio P. Bañ ; ez ; Francisco T. Roxas ; Catherine Lynn T. Silao ; Jose B. Nevado Jr. ; Alberto B. Roxas ; Oliver G. , Florendo ; Ma. Cecilia M. Sison ; Orlino Bisquera, Jr ; Luminardo M. Ramos ; Elizabeth A. Nuqui ; Arnold Joseph M. Fernandez ; Maria Constancia O. Carrillo ; Beatriz J. Tiangco ; Aileen D. Wang ; Rosalyn H. Sebastian ; Richmond B. Ceniza ; Leander Linus Philip P. Simpao ; Lakan U. Beratio ; Eleanor A. Dominguez ; Albert B. Albay Jr. ; Alfredo Y. Pontejos Jr. ; Nathaniel W. Yang ; Arsenio A. Cabungcal ; Rey A. Desales ; Nelia S. Tan-Liu ; Sullian S. Naval ; Roberto M. Montevirge ; Catalina de Siena E. Gonda-Dimayacyac ; Pedrito Y. Tagayuna ; John A. Coloma ; Gil M. Vicente ; Higinio T. Mappala ; Alex C. Tapia ; Emmanuel F. Montana Jr. ; Jonathan M. Asprer ; Reynaldo O. Joson ; Sergio P. Paguio ; Tristan T. Chipongian ; Joselito F. David ; Florentino C. Doble ; Maria Noemi G. Pato ; Benito B. Bionat Jr ; Hans Francis D. Ferraris ; Adonis A. Guancia ; Eriberto R. Layda ; Andrew D. Dimacali ; Conrado C. Cajucom ; Richard C. Tia ; Mark U. Javelosa ; Regie Lyn P. Santos-Cortez ; Frances Maureen C. Rocamora ; Roemel Jeusep Bueno ; Carmencita D. Padilla
Acta Medica Philippina 2017;51(3):216-222
Objectives. Polymorphisms in metabolic genes which alter rates of bioactivation and detoxification have been shown to modulate susceptibility to colorectal cancer. This study sought to evaluate the colorectal cancer risk from environmental factors and to do polymorphism studies on genes that code for Phase I and II xenobiotic metabolic enzymes among Filipino colorectal cancer patients and matched controls. Methods. A total of 224 colorectal cancer cases and 276 controls from the Filipino population were genotyped for selected polymorphisms in GSTM1, GSTP1, GSTT1, NAT1 and NAT2. Medical and diet histories, occupational exposure and demographic data were also collected for all subject participants.Results. Univariate logistic regression of non-genetic factors identified exposure to UV (sunlight) (OR 1.99, 95% CI: 1.16-3.39) and wood dust (OR 2.66, 95% CI: 1.21-5.83) and moldy food exposure (OR 1.61, 95% CI:1.11-2.35) as risk factors; while the NAT2*6B allele (recessive model OR 1.51, 95% CI :1.06-2.16; dominant model OR 1.87, 95% CI: 1.05-3.33) and homozygous genotype (OR 2.19, 95% CI: 1.19-4.03) were found to be significant among the genetic factors. After multivariate logistic regression of both environmental and genetic factors, only UV radiation exposure (OR 2.08, 95% CI: 1.21-3.58) and wood dust exposure (OR 2.08, 95% CI: 0.95-5.30) remained to be significantly associated with increasing colorectal cancer risk in the study population.Conclusion. This study demonstrated that UV sunlight and wood dust exposure play a greater role in influencing colorectal cancer susceptibility than genotype status from genetic polymorphisms of the GST and the NAT` genes.
Colorectal Neoplasms
;
Polymorphism, Genetic
6.Intravenous tocilizumab versus standard of care in the treatment of severe and critical COVID-19-related pneumonia: A single center, double-blind, placebo controlled, phase 3 trial
Eric Jason B. Amante ; Aileen S. David-Wang ; Michael L. Tee ; Felix Eduardo R. Punzalan ; John C. Añ ; onuevo ; Lenora C. Fernandez ; Albert B. Albay Jr. ; John Carlo M. Malabad ; Fresthel Monica M. Climacosa ; A. Nico Nahar I. Pajes ; Patricia Maria Gregoria M. Cuañ ; o ; Marissa M. Alejandrí ; a
Acta Medica Philippina 2024;58(6):7-13
Background:
Severe and critical COVID-19 disease is characterized by hyperinflammation involving pro-inflammatory cytokines, particularly IL-6. Tocilizumab is a monoclonal antibody that blocks IL-6 receptors.
Objectives:
This study evaluated the efficacy of tocilizumab in Filipino patients with severe to critical COVID-19 disease.
Methods:
This phase 3 randomized double-blind trial, included patients hospitalized for severe or critical COVID-19 in a 1:1 ratio to receive either tocilizumab plus local standard of care or placebo plus standard of care. Patients were eligible for a repeat IV infusion within 24-48 hours if they deteriorated or did not improve. Treatment success or clinical improvement was defined as at least two categories of improvement from baseline in the WHO 7-point Ordinal Scale of patient status, in an intention-to-treat manner.
Results:
Forty-nine (49) patients were randomized in the tocilizumab arm and 49 in the placebo arm. There was no significant difference in age, comorbidities, COVID-19 severity, need for mechanical ventilation, presence of acute respiratory distress syndrome, or biomarker levels between groups. Use of adjunctive therapy was similar between groups, with corticosteroid used in 91.8% in tocilizumab group and 81.6% in the placebo group, while remdesivir was used in 98% of participants in both groups. There was no significant difference between groups in terms of treatment success in both the intention-to-treat analysis (relative risk=1.05, 95% CI: 0.85-1.30) and per-protocol analysis (relative risk=0.98, 95% CI: 0.80 to 1.21). There was no significant difference in time to improvement of at least two categories relative to baseline on the 7-point Ordinal Scale of clinical status.
Conclusion
The use of tocilizumab on top of standard of care in the management of patients with severe to critical COVID-19 did not result in significant improvement as defined by the WHO 7-point Ordinal Scale of patient status, nor in significant improvement in incidence of mechanical ventilation, incidence of ICU admission, length of ICU stay, and mortality rate.
COVID-19
;
Interleukin-6